The following is a summary of “Long-term effectiveness of aripiprazole once monthly on functioning and quality of life in schizophrenia: results of year 2 of the ReLiAM study,” published in the ...
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...
The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory ...
Even after controlling for a person’s existing substance use and mental health disorders, there remained a 3.5-fold increased ...
AbbVie (ABBV) shares dropped 11% premarket as late-stage trials for schizophrenia drug emraclidine did not meet primary ...
(OLE) trial – – Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine’s improvement on negative ...
Cerevel wasn't a one-trick pony, however. For its considerable spend, AbbVie also acquired several other pipeline programs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback